Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Zipalertinib |
Synonyms | |
Therapy Description |
Zipalertinib (CLN-081) is a small molecule tyrosine kinase inhibitor with selective activity against EGFR mutations including exon 20 insertions, potentially resulting in decreased Egfr signaling and growth inhibition of EGFR-mutant tumors (PMID: 29748209, PMID: 31467113). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Zipalertinib | CLN-081|CLN 081|CLN081|TAS6417|TAS-6417 | EGFR Inhibitor (Pan) 62 | Zipalertinib (CLN-081) is a small molecule tyrosine kinase inhibitor with selective activity against EGFR mutations including exon 20 insertions, potentially resulting in decreased Egfr signaling and growth inhibition of EGFR-mutant tumors (PMID: 29748209, PMID: 31467113). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05967689 | Phase II | Zipalertinib | A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2) | Recruiting | USA | TUR | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT05973773 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Zipalertinib Carboplatin + Pemetrexed Disodium + Zipalertinib Pemetrexed Disodium Cisplatin + Pemetrexed Disodium + Zipalertinib | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3) | Recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BEL | 4 |
NCT04036682 | Phase Ib/II | Zipalertinib | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1) | Active, not recruiting | USA | NLD | ITA | ESP | 5 |